The Inflation Reduction Act (IRA) recently overhauled Medicare’s prescription drug coverage, including imposing a new $2,000 cap on enrollees’ out-of-pocket spending. In practice, this cap is likely more generous than many observers realize and may be contributing to instability in the market.